Abstract 492P
Background
Surgery is one of the necessary treatment methods for breast cancer patients. However, wound caused by surgery is the main source of clinically related stress stimulation, and can promote tumor metastasis. Currently, as an important component of the tumor microenvironment, myeloid-derived suppressor cells (MDSC) have become a hotspot in the study of tumor metastasis.
Methods
We comprehensively explored the influence of wound stress on tumor growth, EMT related metastasis, and the recruitment of MDSC in the tumor microenvironment in a subcutaneous 4T1 tumor model.
Results
We found that wound stress stimulation promoted breast cancer growth and lung metastasis in mice, and enhanced the recruitment of stressed MDSC in the tumor microenvironment. The expression of Vimentin increased, suggesting EMT transformation. In vitro, bone marrow MDSC cells from mice undertaking stress stimulation promoted the EMT transformation in 4T1. The exosomes were extracted and the expression of mmu-miR-126a-5p was low in stressed MDSC exosomes. Mmu-miR-126a-5p overexpression suppressed tumor growth, lung metastasis and EMT transformation. Through the database screening of the target gene of mmu-miR-126a-5p combined with the results of sequencing analysis, CXCL12 was predicted to be the target gene of mmu-miR-126a-5p, which was verified by double luciferase reporting assay. CXCL12 and CXCR4 were highly expressed in the wound stress stimulation model, indicating mmu-miR-126a-5p induces breast cancer EMT transformation by targeting CXCL12/CXCR4 axis.
Conclusions
Here, we found that surgical stress stimulation can elicit the recruitment of stressed MDSC in the tumor microenvironment. Reduced exosome miR-126a-5p released by stressed MDSC leads to EMT transformation of tumor cells by attenuating the inhibition of CXCL12/CXCR4 axis in 4T1 cells and ultimately promotes increased lung metastasis. From the perspective of tumor microenvironment, these findings explain the phenomenon of increased lung metastasis caused by surgical stress stimulation and optimize new targets for MDSC, thus providing new ideas for breast cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
466P - Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
Presenter: Lei Tang
Session: Poster session 04
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04